These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 34889374)

  • 1. AL amyloidosis: untangling new therapies.
    Bal S; Landau H
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):682-688. PubMed ID: 34889374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-based immunotherapy for treatment of immunoglobulin light-chain amyloidosis.
    Parrondo RD; Majeed U; Sher T
    Br J Haematol; 2020 Dec; 191(5):673-681. PubMed ID: 32298469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interest of daratumumab in refractory AL amyloidosis in a 96-year-old patient].
    Vial G; Lafargue A; Mercié P; Duffau P; Ribeiro E
    Rev Med Interne; 2022 Nov; 43(11):673-676. PubMed ID: 35934598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AL amyloidosis: Singapore Myeloma Study Group consensus guidelines on diagnosis, treatment and management.
    Tan M; Chen Y; Ooi M; de Mel S; Tan D; Soekojo C; Tso A; Khoo CY; Tan HZ; Choo J; Lee LK; Diong CP; Goh YT; Hwang W; Linn YC; Ho A; Chng WJ; Nagarajan C
    Ann Acad Med Singap; 2023 Nov; 52(11):601-624. PubMed ID: 38920149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonchemotherapy Treatment of Immunoglobulin Light Chain Amyloidosis.
    Van Doren L; Lentzsch S
    Acta Haematol; 2020; 143(4):373-380. PubMed ID: 32526750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibril-directed Therapies in Systemic Light Chain AL Amyloidosis.
    Bhutani D; Leng S; Lentzsch S
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):555-559. PubMed ID: 31262668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in understanding and treating immunoglobulin light chain amyloidosis.
    Badar T; D'Souza A; Hari P
    F1000Res; 2018; 7():. PubMed ID: 30228867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
    Lee H; Tay J; Duggan P; McCulloch S; Neri P; Bahlis NJ; Jimenez-Zepeda VH
    Eur J Haematol; 2021 Mar; 106(3):340-345. PubMed ID: 33197297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of AL amyloidosis in 2020.
    Palladini G; Milani P; Merlini G
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):363-371. PubMed ID: 33275753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
    Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
    J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021.
    Hasib Sidiqi M; Gertz MA
    Blood Cancer J; 2021 May; 11(5):90. PubMed ID: 33993188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment strategy for immunoglobulin light chain amyloidosis].
    Fuchida SI
    Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supportive Care in AL Amyloidosis.
    Cibeira MT; Ortiz-Pérez JT; Quintana LF; Fernádez de Larrea C; Tovar N; Bladé J
    Acta Haematol; 2020; 143(4):335-342. PubMed ID: 32235118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of the elderly patient with AL amyloidosis.
    Nuvolone M; Milani P; Palladini G; Merlini G
    Eur J Intern Med; 2018 Dec; 58():48-56. PubMed ID: 29801808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The significance of free light chain measurements in the diagnosis of myelomatous pleural effusion.
    Tsukamoto A; Yoshiki Y; Yamazaki S; Kumano K; Nakamura F; Kurokawa M
    Ann Hematol; 2014 Mar; 93(3):507-8. PubMed ID: 23797638
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update.
    Muchtar E; Dispenzieri A; Gertz MA; Kumar SK; Buadi FK; Leung N; Lacy MQ; Dingli D; Ailawadhi S; Bergsagel PL; Fonseca R; Hayman SR; Kapoor P; Grogan M; Abou Ezzeddine OF; Rosenthal JL; Mauermann M; Siddiqui M; Gonsalves WI; Kourelis TV; Larsen JT; Reeder CB; Warsame R; Go RS; Murray DL; McPhail ED; Dasari S; Jevremovic D; Kyle RA; Lin Y; Lust JA; Russell SJ; Hwa YL; Fonder AL; Hobbs MA; Rajkumar SV; Roy V; Sher T
    Mayo Clin Proc; 2021 Jun; 96(6):1546-1577. PubMed ID: 34088417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiorgan involvement by amyloid light chain amyloidosis.
    Li G; Han D; Wei S; Wang H; Chen L
    J Int Med Res; 2019 Apr; 47(4):1778-1786. PubMed ID: 30803274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.